Cra Headlands LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$5,212,594	370
2024	Research	$6,127,171	233
2023	Research	$8,546,265	4,321
2022	Research	$4,083,865	184
2021	Research	$3,936,305	123
2020	Research	$121,143	8
2019	Research	$8,138	5

Breakdown

Who paid Research payments · program years 2019–2025

Moderna TX, Inc. $14,770,180 4,627 payments
Pfizer Inc. $11,269,752 419 payments
AstraZeneca Pharmaceuticals LP $620,138 5 payments
Novavax Inc $509,826 42 payments
GlaxoSmithKline, LLC. $429,048 41 payments
AbbVie, Inc. $322,726 72 payments
Janssen Pharmaceuticals, Inc $111,816 36 payments
ALK-Abello, Inc $1,995 2 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $2,981,819 80 payments
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $2,674,516 2,662 payments
A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $1,694,854 40 payments
A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $1,681,542 65 payments
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age $1,633,412 62 payments
A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $1,288,611 58 payments
A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $1,143,543 29 payments
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $1,021,246 42 payments
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $817,686 25 payments
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $809,817 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.